Tyrosine Kinase Inhibitor
VIDEO: New findings from phase 2 STRIDE trial presented at AAD
In this video, Raj Chovatiya, MD, PhD, discusses findings from the phase 2 STRIDE trial presented at this year’s American Academy of Dermatology Annual Meeting.
‘It is encouraging’: Sotyktu sails through phase 3 trial in psoriatic arthritis
Sotyktu significantly outperformed placebo for the treatment of psoriatic arthritis in a phase 3 trial, meeting key endpoints at 16 weeks, according to late-breaking data presented at the American Academy of Dermatology annual meeting.
Transforming Glaucoma Care With Rho Kinase Inhibitors
This activity is supported by an educational grant from Alcon Vision, LLC.
Tyrosine Kinase Inhibitors: Transforming nAMD Treatment
This activity is supported by an educational grant from EyePoint Pharmaceuticals, Inc.
Tyrosine Kinase Inhibitors and Their Role in Redefining Retinal Care
This activity is supported by an educational grant from Ocular Therapeutix, Inc.
‘Coming to the clinic soon’: Top AAD takeaways from Joel M. Gelfand, MD, MSCE
ORLANDO — The American Academy of Dermatology annual meeting was packed with “massive advancements” across the field, Joel M. Gelfand, MD, MSCE, chief medical editor of Healio Dermatology, said.
VIDEO: Bruton tyrosine kinase inhibitor studied in immune thrombocytopenia
In this video, Ronak Mistry, DO, discusses the results of a study presented at ASH Annual Meeting that examined the use of the Bruton tyrosine kinase inhibitor rilzabrutinib in patients with immune thrombocytopenic purpura.
VIDEO: ‘Intriguing’ psoriatic arthritis treatments in the pipeline
Ethan Craig, MD, spoke with Healio about treatment options coming up in the pipeline for psoriatic arthritis.
VIDEO: Tyrosine kinase inhibitors offer new mechanism of action for VEGF inhibition
In this Healio Video Perspective from the Retina Society meeting, Sumit Sharma, MD, of Cole Eye Institute discusses how tyrosine kinase inhibitors differ from other treatment options for retinal diseases.